An atypical antidepressant is any antidepressant that doesn’t fit neatly into the major drug classes like SSRIs, SNRIs, tricyclics, or MAOIs. The name is a catch-all: these medications each work through different brain chemistry pathways, and the only thing they truly share is that they don’t belong anywhere else. They’re prescribed for depression, but several have become go-to treatments for insomnia, smoking cessation, and anxiety as well.
Why They’re Called “Atypical”
Most antidepressants fall into well-defined categories based on how they work. SSRIs act mainly on a single brain chemical, serotonin. SNRIs block the reabsorption of both serotonin and norepinephrine. Tricyclics and MAOIs are older classes with broader, less targeted effects. Atypical antidepressants don’t follow any of these playbooks. Some boost dopamine, others block specific serotonin receptor subtypes, and others increase the release of multiple brain chemicals at once without blocking their reabsorption at all.
Because these drugs work through such varied mechanisms, they often fill gaps that standard antidepressants can’t. Someone who experiences intolerable side effects on an SSRI, for example, might do well on an atypical that avoids serotonin pathways entirely.
Bupropion: The Dopamine and Norepinephrine Option
Bupropion is probably the most widely recognized atypical antidepressant. It works by blocking the reabsorption of dopamine and norepinephrine, and it has essentially no effect on serotonin. That distinction matters for two reasons: it carries a much lower risk of sexual side effects, and it doesn’t cause the weight gain common with many other antidepressants.
The difference in sexual side effects is substantial. In one study, 73% of people taking an SSRI reported sexual side effects compared to 14% on bupropion. A separate trial found that 63% of men on sertraline (an SSRI) developed sexual dysfunction versus 15% of men on bupropion. For many people, this alone makes bupropion a more sustainable long-term option.
Beyond depression, bupropion is FDA-approved as a smoking cessation aid. Its effect on dopamine reabsorption helps reduce cravings and withdrawal symptoms, roughly doubling quit rates compared to placebo or nicotine patches. It’s also used for seasonal affective disorder and has shown effectiveness for ADHD. Clinicians sometimes add it to an SSRI regimen to counteract sexual side effects or boost the antidepressant response.
The main safety concern with bupropion is seizure risk. At doses up to 450 mg per day, the risk is low. Between 450 and 600 mg per day, the seizure rate jumps nearly tenfold. Because of this, bupropion is not appropriate for people with seizure disorders, eating disorders like bulimia or anorexia (which raise seizure risk independently), or anyone abruptly stopping alcohol or sedatives.
Mirtazapine: Sedation and Appetite as Features
Mirtazapine takes a completely different approach. Rather than blocking the reabsorption of brain chemicals, it increases the release of both serotonin and norepinephrine by blocking a receptor that normally acts as a brake on their production. It also strongly blocks histamine receptors, which is why it causes significant drowsiness and increased appetite.
Those side effects sound undesirable on paper, but for certain patients they’re exactly what’s needed. Someone with depression accompanied by severe insomnia and weight loss may benefit from a medication that promotes sleep and stimulates appetite. Mirtazapine also has anti-nausea properties, making it useful for people dealing with both depression and gastrointestinal distress.
Sexual side effects with mirtazapine are lower than with SSRIs, though not as low as with bupropion. One large study found rates of 24% for mirtazapine compared to 58% to 71% for common SSRIs and SNRIs. The trade-off is the sedation and potential weight gain, which are more pronounced than with most other antidepressants.
Trazodone: More Sleep Aid Than Antidepressant in Practice
Trazodone is technically an antidepressant, but it’s prescribed far more often for insomnia. The reason comes down to dosing. At low doses (25 to 100 mg), trazodone blocks receptors involved in wakefulness and arousal, producing a sedating effect without the full antidepressant action. To actually treat depression, doses need to reach 150 to 600 mg, at which point it also blocks serotonin reabsorption.
Earlier use of trazodone focused on high-dose treatment for depression with insomnia. Since the 2000s, low-dose trazodone has become a common off-label choice for sleep problems in people who aren’t depressed at all. It’s often preferred over dedicated sleep medications because it doesn’t carry the same risk of dependence.
Newer Multimodal Antidepressants
A newer generation of atypical antidepressants works through what researchers call “multimodal” mechanisms, meaning they combine two or more distinct pharmacological actions in a single drug. Vilazodone, approved in 2011, blocks serotonin reabsorption like an SSRI but also partially activates a specific serotonin receptor. The idea behind this combination is to speed up the antidepressant response. Standard SSRIs can take weeks to fully work partly because certain serotonin receptors initially slow down the brain’s serotonin signaling. By directly activating those receptors, vilazodone may bypass some of that delay.
Vortioxetine takes multimodal action even further. It blocks serotonin reabsorption while also interacting with several different serotonin receptor subtypes, including some involved in sleep, circadian rhythm, and mood regulation. In preclinical comparisons with fluoxetine (Prozac), vortioxetine produced a noticeably faster recovery of serotonin nerve cell activity, partly due to its additional receptor-blocking effects. Vortioxetine has also drawn attention for potential benefits on cognitive symptoms of depression, like difficulty concentrating and mental fog.
How Atypical Antidepressants Are Used
Atypical antidepressants serve several roles in treatment. They’re sometimes prescribed as a first choice when a standard SSRI’s side effect profile is a poor fit. Someone concerned about sexual side effects or weight gain, for instance, might start with bupropion rather than trying an SSRI first. They’re also a common second step for people who tried an SSRI and either didn’t respond well or couldn’t tolerate the side effects.
Another important use is augmentation, where an atypical antidepressant is added to an existing medication rather than replacing it. Bupropion is frequently combined with SSRIs to improve the overall antidepressant effect or offset specific side effects. Mirtazapine is sometimes paired with an SSRI or SNRI for the same reason, a combination informally known in clinical settings for its complementary mechanisms.
For treatment-resistant depression, where someone hasn’t responded to at least one adequate course of antidepressant therapy, the strategy often shifts to adding medications from outside the antidepressant category altogether. Three atypical antipsychotic drugs (a different class from atypical antidepressants, despite the confusing naming) have FDA approval as add-on treatments for this situation, and they’re effective at reducing depressive symptoms, though they come with their own side effects including sedation and weight gain.
Comparing Side Effect Profiles
The clearest advantage of atypical antidepressants as a group is their different side effect trade-offs compared to SSRIs. Where SSRIs tend to cluster around similar problems (sexual dysfunction, emotional blunting, weight changes), atypicals spread out across a wider range of effects that can be matched to what a given person actually needs or can tolerate.
- Bupropion: Low risk of sexual dysfunction and weight gain. Can cause insomnia, dry mouth, and in rare cases, seizures at high doses. Tends to be mildly activating rather than sedating.
- Mirtazapine: Pronounced sedation and appetite increase. Lower sexual side effect risk than SSRIs. Often helpful when insomnia or poor appetite are part of the depression picture.
- Trazodone: Strong sedation at any dose. Useful for sleep, but daytime drowsiness can be a problem. Rarely used at antidepressant doses anymore due to sedation burden.
- Vilazodone and vortioxetine: Side effect profiles closer to SSRIs since they still involve serotonin, but potentially with faster onset and different tolerability patterns. Nausea and diarrhea are common early side effects.
The “best” atypical antidepressant depends entirely on which symptoms are most troubling and which side effects are most acceptable. That individual matching is the real clinical value of having a category this diverse.